Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Feb 13;12(2):e0170819.
doi: 10.1371/journal.pone.0170819. eCollection 2017.

A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer

YiQuan Xiong  1 , JianDong Li  1 , ShuJuan Ma  2 , Jing Ge  1 , LiZhi Zhou  3 , Dongliang Li  1 , Qing Chen  1
Affiliations
Meta-Analysis

A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer

YiQuan Xiong et al. PLoS One. .

Abstract

Objectives: To assess the additional detection rate (ADR) of within-patient comparisons of Narrow band imaging (NBI) and white light cystoscopy (WLC) for non-muscle invasive bladder cancer (NMIBC) detection and compare the impact of NBI and WLC on bladder cancer recurrence risk.

Methods: We searched relevant studies from PubMed, Embase, Medline, Web of Science and the Cochrane Library database for all articles in English published beforeJuly26th, 2016. Pooled ADR, diagnostic accuracy, relative risk (RR) and their 95% confidence intervals (CIs) were calculated.

Results: Twenty-five studies including 17 full texts and eight meeting abstracts were included for analysis. Compared to WLC, pooled ADR of NBI for NMIBC diagnosis was 9.9% (95% CI: 0.05-0.14) and 18.6% (95% CI: 0.15-0.25) in per-patient and per-lesion analysis, respectively. Pooled ADR of NBI for carcinoma in situ (CIS) diagnosis was 25.1% (95% CI: 0.09-0.42) and 31.1% (95% CI: 0.24-0.39) for per-patient and per-lesion analyses, respectively. The pooled sensitivity of NBI was significantly higher than WLC both at the per-patient (95.8% vs. 81.6%) and per-lesion levels (94.8% vs. 72.4%). In addition, NBI significantly reduced the recurrence rate of bladder cancer with a pooled RR value of 0.43 (95% CI: 0.23-0.79) and0.81 (95% CI: 0.69-0.95) at month three and twelve, respectively.

Conclusions: NBI is a valid technique that improves the diagnosis of NMIBC and CIS compared to standard WLC either at per-patient or per-lesion level. It can reduce the recurrence rate of bladder cancer accordingly.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. The PRISMA checklist for this meta-analysis.
Fig 2
Fig 2. Forest plot of the pooled additional detection rate (ADR) of Narrow-band imaging (NBI) when compared to White light cystoscopy (WLC) for non-muscle invasive bladder cancer (NMIBC) detection in per-patient analysis.
Fig 3
Fig 3. Forest plot of the pooled additional detection rate (ADR) of Narrow-band imaging (NBI)when compared toWhite light cystoscopy (WLC)for non-muscle invasive bladder cancer (NMIBC) detection in per-lesion analysis.
Fig 4
Fig 4
Forest plot of the pooled additional detection rate (ADR) of Narrow-band imaging (NBI)when compared toWhite light cystoscopy (WLC)for carcinoma in situ (CIS) detection in per-patient (a) and per-lesion analysis (b).
Fig 5
Fig 5
Forest plot of the pooled relative risk (RR) for Narrow-band imaging (NBI) compared to White light cystoscopy (WLC) at month three (a) and twelve (b).
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29. 10.3322/caac.20138 - DOI - PubMed
    1. van Lingen AV, Witjes JA (2013) Current intravesical therapy for non-muscle invasive bladder cancer. Expert Opin Biol Ther 13: 1371–1385. 10.1517/14712598.2013.824421 - DOI - PubMed
    1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. (2008) EAU guidelines onnon-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54: 303–314. 10.1016/j.eururo.2008.04.051 - DOI - PubMed
    1. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. (2007) A comparison ofhexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection ofcarcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178: 68–73;discussion 73. 10.1016/j.juro.2007.03.028 - DOI - PubMed
    1. Zlatev DV, Altobelli E, Liao JC (2015) Advances in imaging technologies in the evaluation of high-grade bladder cancer. Urol Clin North Am 42: 147–vii. 10.1016/j.ucl.2015.01.001 - DOI - PMC - PubMed

Publication types

MeSH terms